Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
Stanford scientists have discovered that blocking an immune receptor signal can lead to increased fat uptake and weight reduction in patients suffering from obesity and associated diseases.
Stanford researchers have found that a chemokine receptor antagonist can reduce immunosuppression in the tumor microenvironment and thereby delay tumor progression.
There are two subsets of Hematopoietic stem cells (HSC); one subset that provides balanced production of myeloid and lymphoid cells, and another that is biased toward production of the myeloid lineage.
Stanford scientists have developed a strategy that enables simultaneous and combinatorial genetic screening across different types of genetic perturbations (gene knockouts, knock-ins, overexpression, and gene domain modification).
The recognition of peptide-MHC (pMHC) complexes by T cells is the cornerstone of cellular immunity, enabling the elimination of infected or tumoral cells. pMHC can thus be leveraged as a detection tool for T cells.
Stanford scientists designed a nanobody platform to inhibit the activity of granulysin, a protein that is often found in arterial plaque and released by T cells, to prevent the development of atherosclerosis such as heart attack and strokes.
Researchers at Stanford have discovered that nanobodies blocking amphiregulin (AREG) activity have the potential to impede the progression of early-stage atherosclerotic plaque lesions to advanced-stage fibroatheromas.
Stanford researchers have designed a nanobody platform to selectively block a key region on T cells found within arterial plaque, with the aim of preventing thrombotic complications and myocarditis.
Stanford scientists have discovered that bispecific antibodies can selectively bind cancer cells and block the CD47-SIRPα "don't eat me signal" to efficiently clear tumors with negligible toxicity.
Researchers at Stanford have identified the use of the drug verteporfin to treat or reduce the risk of developing ibrosis after ocular procedures or ocular injury. Of interest is corneal injury, for example after refractive surgery or crosslinking, e.g.
Researchers at Stanford have developed innovative Verteporfin conjugates that considerably enhance the solubility and therapeutic potential of Verteporfin.
Selective cytotoxicity, or the ability to selectively remove certain cell types from a population, is a vital technology that is often applied to various therapeutic applications.